Eric Fischer

Eric Fischer has an extensive work experience spanning multiple roles and companies. In recent years, they co-founded and served as a Scientific Advisory Board (SAB) member at both Neomorph, Inc. and Civetta Therapeutics. Prior to this, Eric worked as an Associate Professor and Assistant Professor at Harvard Medical School, with their tenure starting in 2015. Eric also held the position of Director at the DFCI Center for Protein Degradation starting in 2018. Before their time at Harvard, Eric was a Principal Investigator at the Dana-Farber Cancer Institute, starting in 2015.

Eric's earlier experiences include being a Postdoctoral Fellow, PhD Student, and Master Thesis candidate at the Friedrich Miescher Institute for Biomedical Research. Eric also owned useKit AG, their own company, from 2008 to 2015. Prior to that, Eric was a Technical Director at fgi Fischer Group International GmbH from 2002 to 2010. Eric completed an internship at Roche Diagnostics in 2005 and had a civilian service role at Universitätsklinikum Hamburg Eppendorf from 2001 to 2002.

Eric Fischer has a diverse educational background in the field of biology, molecular biology, biochemistry, biophysics, and molecular biology. Eric completed their Doctor of Philosophy (PhD) from the University of Basel between 2010 and 2013, with a focus on Biochemistry, Biophysics, and Molecular Biology. Prior to that, they obtained their MSc. degree in molecular biology from the University of Basel from 2008 to 2009. Eric Fischer began their undergraduate studies at the University of Basel in 2005, where they received their BSc. degree in Biology in 2008. Before joining the University of Basel, they pursued academic studies at the University of Hamburg from 2003 to 2005, although the specific degree obtained is not provided.